May 18, 2021 -- Gamma Biosciences has purchased a controlling stake in Mirus Bio, a developer of lipid-polymer nanocomplexes for nucleic acid delivery.
The deal expands Gamma Biosciences' reach in gene therapy and next-generation vaccines, while supporting the launch of Mirus Bio's flagship TransIT VirusGen platform for manufacturing of adeno-associated viruses (AAV) and lentivirus-based viral vectors for gene therapy. The investment will also help to further develop and commercialize TransIT VirusGen for in vivo delivery applications, according to the companies.
Terms of the agreement were not disclosed.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
